Cobra signs MOU to form JV with Viromed
UK-listed Cobra Biomanufacturing has extended its manufacturing agreement and intends to form a joint venture with South Korea's ViroMed, a specialist in the development of DNA and protein-based therapeutics.
The extended collaboration with Cobra includes a long-term research, development and technical consultancy agreement for all ViroMed products. The agreement will provide the latter with guaranteed process development and manufacturing resources.
Additionally, the companies have signed a memorandum of understanding to explore the potential of establishing a joint venture commercial scale biomanufacturing company that would enable the partnership to manufacture ViroMed products for commercial supply, at new facilities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze